Business Context and Reporting Period
This Form 8-K is filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) for the reporting period of April 13, 2018, with a signature date of April 17, 2018. The filing addresses the amendment of corporate bylaws regarding new preferred stock and the completion of a public offering.
Key Financial Metrics
- Capital Raised: The Company completed a public offering of common stock, Series C Preferred Stock, and warrants.
- Gross Proceeds: $11.25 million.
- Net Proceeds: Approximately $10.1 million after deducting placement agent fees and estimated offering expenses.
- Stockholders' Equity: As of April 17, 2018, the Company believes it holds stockholders' equity greater than $2.5 million.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes
- Series C Preferred Stock: The Company filed a Certificate of Designation for Series C Convertible Preferred Stock. These shares are convertible into common stock at the holder's option, subject to a 4.99% beneficial ownership limitation (increasable to 9.99%). They generally carry no voting rights except for specific protective provisions and rank on parity with common stock on an as-converted basis.
- Nasdaq Compliance: The Company previously received notice of non-compliance with Nasdaq Listing Rule 5550(b)(1) due to insufficient stockholders' equity (minimum $2.5 million required). The net proceeds from the offering have restored compliance.
Outlook, Risks, and Management Commentary
- Listing Status: While the Company believes it has regained compliance, Nasdaq will continue to monitor the situation. If the Company fails to evidence compliance in its next periodic report, its common stock may be subject to delisting.
- Dividends: Series C Preferred Stock is not entitled to dividends unless specifically declared by the Board of Directors.
- Conversion Restrictions: Holders of Series C Preferred Stock are prohibited from converting shares if the conversion would result in ownership exceeding 4.99% of outstanding common stock.
Investor Verification Checklist
- Verify the final confirmation from Nasdaq that the compliance matter regarding stockholders' equity has been officially closed.
- Review the full Certificate of Designation (Exhibit 3.1) for detailed terms regarding the Series C Preferred Stock conversion and voting rights.
- Confirm the actual use of the $10.1 million in net proceeds as disclosed in subsequent filings.
- Monitor future periodic reports to ensure continued compliance with Nasdaq listing requirements.